Cyclacel Pharmaceuticals (CYCC) 1.05 $CYCC Midd
Post# of 64072
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 11:45AM CST
BV: 6.12 (-0.14), SPPR: 1.80 (-0.13), XPLR: 6.05 (-0.03), PHMD: 1.85 (unch), BOBE: 46.26 (-1.50), NVGN: 3.15 (+0.17), PDII: 1.58 (-0.05), EFUT: 4.38 (-0.02), CECO: 5.90 (-0.10), CENX: 16.08 (-0.41), VEEV: 24.63 (-0.10), CDI: 13.95 (-0.46), CYCC: 1.05 (-0.01), FSTR: 37.22 (-0.61), ANF: 20.17 (-0.04), CNDO: 3.28 (-0.09), NPTN: 4.08 (-0.06), PTN: 1.06 (+0.01), CAPN: 7.11 (-0.26), IFON: 2.59 (+0.07)
Premarket Gainers / Losers as of 9:10 em
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 8:13AM CST
BV: 6.12 (-0.14), AMRN: 1.78 (+0.11), PHMD: 1.85 (unch), BOBE: 46.26 (-1.50), NVGN: 3.15 (+0.17), EFUT: 4.38 (-0.02), TNET: 33.06 (-0.45), ATOS: 1.97 (-0.04), FAST: 40.55 (-0.07), W: 28.81 (+1.03), TIVO: 11.03 (-0.09), CYCC: 1.05 (-0.01), ANF: 20.17 (-0.04), CYTX: 1.11 (-0.05), AEO: 16.68 (+0.34), AMBA: 64.22 (-0.17), CRMD: 8.25 (+0.49), ONCY: 0.90 (-0.15), EXAS: 24.50 (+2.07), ATHM: 43.84 (-2.99), SOL: 1.54 (-0.09), VEEV: 24.63 (-0.10), OREX: 7.10 (-0.91), NURO: 1.69 (-0.06), ACHN: 11.39 (+0.40), CNDO: 3.28 (-0.09), SWHC: 14.23 (-0.17), IFON: 2.59 (+0.07)
Cyclacel Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Mar 04, 6:28AM CST
CYCC: 1.05 (-0.01)
Nasdaq stocks posting largest volume increases
AP - Tue Mar 03, 5:06PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
OREX: 7.10 (-0.91), GDEF: 10.36 (-0.02), WBB: 17.50 (+0.21), ONCY: 0.90 (-0.15), CYCC: 1.05 (-0.01), DRAM: 2.47 (-0.30), AXPW: 0.18 (-0.01), CMLS: 3.02 (-0.01), SQBK: 25.88 (+0.38), MITL: 9.71 (+0.01), TSRI: 4.63 (-0.24), MBLX: 0.85 (-0.01)
Lots of action in Cyclacel Pharma today
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 12:22PM CST
CYCC: 1.05 (-0.01)
Hot Stock: Cyclacel Pharmaceuticals, Shares Gain 14.7% (CYCC)
Comtex SmarTrend(R) - Mon Mar 02, 10:06AM CST
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is one of today's best performing low-priced stocks, up 14.7% to $1.72 on 29.6x average daily volume. Cyclacel Pharmaceuticals has traded 8.7 million shares thus far today, vs. average volume of 293,000 shares per day. The stock has outperformed the Dow (14.7% to the Dow's 0.7%) and outperformed the S&P 500 (14.7% to the S&P's 0.4%) during today's trading.
CYCC: 1.05 (-0.01)
Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels
PR Newswire - Mon Mar 02, 7:35AM CST
Cutting-edge biotech & nutraceutical products, science-based pharmaceuticals and healthy whole food nutrition products reveal technological advancements are in growing demand for treatments of lifestyle related disorders such as hyperglycemia, obesity, insulin level issues and other serious illnesses and health concerns. Nutraceutical and Biotech Companies in focus today are: RiceBran Technologies (NASDAQ: RIBT), Amira Nature Foods Ltd. (NYSE: ANFI), CEL-SCI Corporation (NYSE: CVM), Mondelez International, Inc. (NASDAQ: MDLZ) and Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC).
HLF: 32.69 (+0.90), RIBT: 4.49 (+0.11), MDLZ: 35.22 (-1.29), CYCC: 1.05 (-0.01), CVM: 1.06 (-0.08), ANFI: 10.28 (-0.92)
Most active Nasdaq-traded stocks
AP - Fri Feb 27, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
FB: 80.00 (-1.21), INTC: 33.19 (-0.54), ATOS: 1.97 (-0.04), HERO: 0.60 (unch), FOX: 33.60 (-0.43), CYCC: 1.05 (-0.01), CYTX: 1.11 (-0.05), AMAT: 23.91 (-0.27), FOXA: 34.49 (-0.38), ARCP: 9.59 (-0.39), ZNGA: 2.54 (+0.13), MSFT: 42.36 (-0.75), AAPL: 126.60 (+0.19), CSCO: 28.92 (-0.38)
More nano cap med firms joining the bullish festivities
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 12:45PM CST
CYCC: 1.05 (-0.01), RGDX: 0.58 (+0.02)
Cyclacel Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 6:13AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York, New York. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Tuesday, February 10, 2015 at 10:00 a.m. EST in the Conrad room.
CYCC: 1.05 (-0.01), CYCCP: 8.00 (-0.14)
Biotech Weekly: When To Dash For The Trash (And When Not To)
Daniel Ward - at Seeking Alpha - Mon Feb 02, 8:40AM CST
KBIO: 0.65 (-0.04), CYCC: 1.05 (-0.01), TRGT: 2.63 (+0.01), SPHS: 0.70 (-0.03), ABIO: 0.87 (+0.12), APPY: 0.56 (-0.02), OCLS: 0.95 (+0.01)
Cyclacel Pharmaceuticals to Present at the Biotech Showcase(TM) 2015 Conference
GlobeNewswire - Tue Jan 06, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) "Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the Biotech Showcase 2015 conference being held at Parc 55 Wyndham San Francisco - Union Square in San Francisco, California. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs at 3:30 p.m. PST on Monday, January 12, 2015.
CYCC: 1.05 (-0.01), CYCCP: 8.00 (-0.14)